tombal
@bertrandtombal
ID: 1332642239248539648
28-11-2020 11:08:00
224 Tweet
732 Takipçi
139 Takip Edilen
Join tombal & me in a fun virtual educational webinar! Link: us02web.zoom.us/webinar/regist… Mirrors of Medicine Marinos Tsiatas MikaLion ANASTASIOS KYRIAZOGLOU Ζenia Saridaki Daniele Raggi Laura Marandino Amalya Sargsyan Myrto K. Moutafi Evangelia (Elina) Vlachou, MD Bernadett Szabados Umang Swami Abhishek Tripathi OncoAlert
Very nice summary of the benefit of LHRH antagonists in patients with prostate cancer and significant LUTS Vérane Achard #EAU2025
How to optimize outcomes in men with biochemical recurrence after local treatment with curative intent. Presentation by tombal. #EAU25 written coverage by Julian Chavarriaga > bit.ly/4hBGcxV European Association of Urology (EAU)
👩🏫 If you are attending the EAU Congress 2025 in Madrid, do not miss Dr Fred Saad's oral presentation on the EORTC-GUCG 1333/PEACE-3 trial today at 13:45 CET. More info available here: scientific-programme.uroweb.org/EAU25/programme #EAU25 #CancerResearch #ClinicalTrials #Oncology #EORTCgenitourinary
Data from Peace3 presented by Fred Saad clearly suggest that early administration of bone protecting agent increase rPFS and OS in patients receiving enzalutamide +- Ra223 EORTC GETUG SOGUG LACOG - Latin American Cooperative Oncology Group silke gillessen #EAU2025
Sharpen your approach to mCRPC with the latest, most revolutionary trial data, and expert guidance via tombal Pedro C Barata, MD MSc FACP Alicia Morgans, MD, MPH on applying it to your practice. ICYMI at major meetings this year 💥 ms.spr.ly/6017Sd2rH
In PEACE-3 (EORTC 1333), the addition of 6 cycles of Ra223 to enzalutamide improves PSA response time and rates (≥90%), ALP reduction time (≥30%), and ALP normalization at 6 and 12 months. EORTC silke gillessen Andrey Soares GETUG CancerTrialsIreland 🌈 SOGUG
Are we ready for ARPI alone therapy in mCSPC? Is a non-inferiority trial needed? Great lecture by tombal at #UROonco25 in Sevilla but the debate is still open... European Association of Urology (EAU) European Urology OncoDaily OncoAlert UroFocus Alessandro Volpe Morgan Roupret
Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from Vérane Achard in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍
🇫🇷🇧🇪Ouverture des JER du GETUG avec le débat sur la prise en charge des mCRPC. ✨ Roubaud Guilhem tombal Helissey carole Bernard-Tessier
🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, Julien Van Damme, Vérane Achard , Laura S. Mertens, Robert Huddart💙, francesco soria, Lars Dyrskjøt, Yves Allory Institut Curie,
It's time to reconsider how we view patient involvement in developing clinical trials, beyond just asking them to review the ICF. Beautyfull work by Laureline Gatellier sciencedirect.com/science/articl…
Systemic treatment for nonmuscle-invasive #BladderCancer: Clinical precision or overreaction? Presentation by Bradley McGregor Dana-Farber. #ESMO25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/47fRBQQ ESMO - Eur. Oncology Ashish M. Kamat, MD, MBBS